Treatment with the COX-2 inhibitor Celecoxib was shown to reduce the collagen-dense tumor burden in glioblastoma, and to enhance radiosensitivity of hypoxic glioblastoma cells [117]. This evidence concerns the gene PTGS2 and glioblastoma.